NEW YORK (Reuters) - Aggressive marketing of Merck & Co.'s new first-in-class diabetes drug Januvia has led to a strong launch, according to data compiled by ImpactRx Inc., a market research company ...
Sitagliptin (Januvia™) is a new oral agent approved by the US FDA to treat Type 2 diabetes. This is the first approved agent in a new class of antihyperglycemics, dipeptidyl peptidase (DPP)-4 ...
(Reuters) - Pfizer Inc and Merck & Co Inc said they will co-develop Pfizer's experimental type 2 diabetes drug ertugliflozin, both as a standalone product and in combination with other drugs, ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results